Here's why Incannex (ASX:IHL) shares are in a trading halt

The pharmaceutical up-and-comer has requested trading in its shares be placed on hold.

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price won't be going anywhere today.  

Shares in the emerging pharmaceutical company were placed in a trading halt before markets opened.

Here's why.

Incannex shares halted on patent update and ethics approval

Having last traded at 27.5 cents, Incannex requested its shares be placed in a trading halt before the market open.

Incannex cited a material patent update and ethics approval for its research studies. The company did not specify which research trial or which patent was in line to receive ethics clearance.  

Incannex noted that its shares will remain in a trading halt until either the commencement of normal trading on 22nd July 2021 or the earlier release of an announcement.

More on Incannex

Incannex is a clinical-stage pharmaceutical development company that develops medicinal cannabis pharmaceutical products and psychedelic medicine therapies.

The company's therapies are designed for various medical issues, including anxiety disorders, sleep apnoea, lung inflammation and rheumatoid arthritis.

Incannex has a pipeline of patents including IHL-216A which targets traumatic brain injury and IHL-42X for sleep apnoea.

The Incannex share price has had a stellar 2021, with shares in the company up more than 80% since the start of the year. On a 52-week basis, the Incannex share price has risen nearly 300%.

Apart from today's announcement, the last piece of price-sensitive news from Incannex was late last week.

The company announced that it engaged Procaps to develop and manufacture its IHL-675A soft gel capsules in preparation for clinical trials.

According to Incannex, its IHL-675A formulation is a multi-use drug that has anti-inflammatory properties. The company also informed investors that it has advanced plans for a phase1 clinical trial to assess IHL-675A soft gel capsules.

Incannex noted that subject to clinical success, the results of the phase 1 clinical trial will form part of 3 US Food and Drug Administration (FDA) applications.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a good start to the week for Aussie investors.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A graphic image of the world globe surrounded by tech images is superimposed on the setting of an office where three businesspeople are speaking together while standing.
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX technology shares led the market with a 2.8% gain this week.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Woman in a hammock relaxing, symbolising passive income.
Dividend Investing

Hoping to retire? I'd buy these ASX 200 dividend shares for passive income

I think these ASX 200 dividend stocks will continue to reward passive income investors for years to come.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 300 shares could rise 35% to 65%

Analysts are tipping these shares to rise strongly from current levels. How high could they go?

Read more »

a man in a high visibility vest and hard hat holds a thumbs up at a mine site with heavy equipment in the background.
Broker Notes

What are brokers saying about BHP shares following the miner's quarterly results?

Analysts have crunched the numbers.

Read more »

A young girls clings in fright to a big red slide.
Share Market News

Here are the top 10 ASX 200 shares today

Investors were hitting the sell button hard today...

Read more »